New drug combo shows early promise against Hard-to-Treat cancers
NCT ID NCT06091930
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times
Summary
This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main goals were to find a safe dose and see if the drugs could shrink tumors. Participants received infusions every three weeks for up to three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 765049 and ezabenlimab
- What this could lead to
- If it works, this could point toward a new treatment option for advanced cancers that have the B7-H6 marker.
- What could go wrong
- This is a very early Phase 1 trial with only 21 participants, so it is too small to prove effectiveness. The drugs may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Your gut bacteria might reveal hidden cancer risk